CClinicalTrials.gg
RecruitingNCT06936449CI-DEX-LTFUUpdated Jul 7, 2026

Long-term Follow-up of a Cochlear Implant With Dexamethasone Eluting Electrode Array

An observational study in Sensorineural Hearing Loss and Bilateral Hearing Loss, sponsored by Cochlear. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Cochlear · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
19
Ages
18 Years and older
Sex
All
01

Study summary

A long-term follow-up of Cochlear's cochlear implant electrode array which passively elutes dexamethasone for a defined period of time to help reduce inflammatory responses.

02

Conditions studied

  • Sensorineural Hearing Loss
  • Bilateral Hearing Loss

Keywords

  • cochlear implant
  • dexamethasone
  • bilateral hearing loss
  • sensorineural hearing loss
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals available from those sites invited to participate in the study consisting of up to 10 subjects implanted with the CI632D and up to 9 subjects with the CI632 in the CIDEX study (NCT04750642)

Inclusion criteria

  • Subjects who completed study obligations of the CLTD5759 CI-DEX study and enrolled at a site selected for participation.
  • Subjects implanted with a CI632D or a CI632 cochlear implant under the CLTD5759 (NCT04750642).
  • Willing and able to provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to participation as determined by the Investigator.
  • Additional disabilities that may affect the subject's participation or safety during the clinical investigation.
  • Unable or unwilling to comply with all the requirements of the clinical investigation as determined by the Investigator.
  • Currently participating, or participated within the last 30 days, in another interventional clinical investigation/trial involving an investigational drug or device.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
19 participants (estimated)
Patient registry
No

Groups and cohorts

  • Experimental: CI632D Investigational Medical Device (IMD)

    Adults with bilateral postlinguistic sensorineural hearing loss, who have received the CI632D cochlear implant

    Device: CI632D

  • Active Comparator: CI632 Comparator Device

    Adults with bilateral postlinguistic sensorineural hearing loss, who have received the CI632 cochlear implant

    Device: CI632

Interventions

  • DeviceCI632D

    CI632 cochlear implant with Slim Modiolar electrode including dexamethasone in the electrode within wells

  • DeviceCI632

    CI632 cochlear implant with Slim Modiolar electrode with market approval and does not include dexamethasone

05

What researchers measure

Primary outcomes

  1. Comparison of Monopolar (MP1+2) Impedance Measurement (kOhms) between groups obtained in the CLTD5759 (NCT04750642) study, and at the 2 through 5 years post-activation routine follow-up visits.

    Time frame: 5 years post-activation

Secondary outcomes

  1. Comparison of CI632D and CI632 device-related adverse events between groups from enrolment in this study through 5 years postactivation.

    Time frame: 5 years post-activation

  2. Comparison of Four-point Impedance Measurement between groups obtained in the CLTD5759 (NCT04750642) study, and from enrolment in this study through 5 years postactivation.

    Time frame: 5 years post-activation

  3. Comparison of low-frequency acoustic hearing between groups as measured by pure tone average thresholds over the range 125 through 500 Hz, obtained in the CLTD5759 (NCT04750642) study and from enrolment in this study through 5 years postactivation.

    Time frame: 5 years post-activation

  4. Comparison of speech perception in quiet (CNC word scores) for the best unilateral listening condition in the implanted ear between groups obtained in the CLTD5759 (NCT04750642) study, and from enrolment in this study through 5 years postactivation.

    Time frame: 5 years post-activation

  5. Speech perception in noise (AzBio sentence scores) for the best bilateral listening condition obtained between groups in the CLTD5759 (NCT04750642) study, and from enrolment in this study through 5 years postactivation.

    Time frame: 5 years post-activation

06

Study locations

3 of 3 sites recruiting
  • Rocky Mountain Ear Center
    Englewood, Colorado 80113, United States
    Recruiting
  • University of Iowa
    Iowa City, Iowa 52242, United States
    Recruiting
  • University Hospitals Cleveland
    Cleveland, Ohio 44106, United States
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06936449
Lead sponsor
Cochlear
Responsible party
Sponsor
First posted
Apr 20, 2025
Start date
May 5, 2025
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Jul 7, 2026

Study contacts

PRS Specialist
Contact
cltd-prs-admin@cochlear.com
+61 2 9428 6555

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion